A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI in Patients With Ras Mutant Positive Metastatic Colorectal Cancer, Either Newly Diagnosed or Previously Treated.

Trial Profile

A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI in Patients With Ras Mutant Positive Metastatic Colorectal Cancer, Either Newly Diagnosed or Previously Treated.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs GI 4000 (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 24 Sep 2014 Planned End Date changed from 1 Oct 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
    • 24 Sep 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top